<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Expert Rev Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Expert Rev Clin Pharmacol</journal-id><journal-title-group><journal-title>Expert Review of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">1751-2433</issn><issn pub-type="epub">1751-2441</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8022338</article-id><article-id pub-id-type="pmid">33706626</article-id><article-id pub-id-type="doi">10.1080/17512433.2021.1903317</article-id><article-id pub-id-type="publisher-id">1903317</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Compounds of plants with activity against SARS-CoV-2 targets</article-title><alt-title alt-title-type="left-running-head">D. J. MARMITT ET AL.</alt-title><alt-title alt-title-type="right-running-head">EXPERT REVIEW OF CLINICAL PHARMACOLOGY</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5454-9099</contrib-id><name><surname>Marmitt</surname><given-names>Diorge J&#x000f4;natas</given-names></name><xref ref-type="aff" rid="aff0001"><sup>a</sup></xref><xref ref-type="corresp" rid="an0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3648-5033</contrib-id><name><surname>Goettert</surname><given-names>M&#x000e1;rcia In&#x000ea;s</given-names></name><xref ref-type="aff" rid="aff0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8573-0237</contrib-id><name><surname>Rempel</surname><given-names>Claudete</given-names></name><xref ref-type="aff" rid="aff0002"><sup>b</sup></xref></contrib><aff id="aff0001"><label>a</label>Programa De P&#x000f3;s-gradua&#x000e7;&#x000e3;o Em Biotecnologia, <institution-wrap><institution>Universidade Do Vale Do Taquari - Univates</institution></institution-wrap>, <city>Lajeado RS</city>, <country>Brazil</country></aff><aff id="aff0002"><label>b</label><institution-wrap><institution>Programa De P&#x000f3;s-gradua&#x000e7;&#x000e3;o Em Ambiente E Desenvolvimento/Programa De P&#x000f3;s-gradua&#x000e7;&#x000e3;o Em Sistemas Ambientais Sustent&#x000e1;veis, Universidade Do Vale Do Taquari &#x02013; Univates</institution></institution-wrap> , <city>Lajeado RS</city>, <country>Brazil</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Diorge J&#x000f4;natas Marmitt <email xlink:href="mailto:diorgemarmitt@yahoo.com.br">diorgemarmitt@yahoo.com.br</email> Programa De P&#x000f3;s-gradua&#x000e7;&#x000e3;o Em Biotecnologia, <institution-wrap><institution>Universidade Do Vale Do Taquari - Univates</institution></institution-wrap>, <addr-line>Diorge J&#x000f4;natas Marmitt Av. Avelino Talini, 171</addr-line>, <city>Lajeado Rs</city>, <postal-code>95914-014</postal-code>, <country>Brazil</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>3</month><year>2021</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><fpage seq="1">1</fpage><lpage>11</lpage><permissions><copyright-statement>&#x000a9; 2021 Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IERJ_0_1903317.pdf"/><abstract><title>ABSTRACT</title><sec id="s2001" sec-type="intro"><title>Introduction</title><p>The COVID-19 global pandemic is a public health emergency due to its high virulence and mortality. Many vaccine development studies at clinical trials are currently conducted to combat SARS-CoV-2. Plants are a rich source of phytochemicals with different biological activities, including antiviral activities, which are the focus of many studies.</p></sec><sec id="s2002"><title>Areas covered</title><p>This review shows compounds of traditional plants listed on RENISUS list have therapeutic properties against SARS-CoV-2 targets.</p></sec><sec id="s2003"><title>Expert Opinion</title><p>The rise of new variants, more pathogenic and virulent, impacts in the increase of mortality from SARS-CoV-2 infection, and thus, the control of the outbreaks of disease remains a global challenge. Other&#x02019;s drug and vaccines development is an essential element in controlling SARS-COV-2. Therefore, it is imperative that approach to tackle this pandemic has to be solidly evidence-informed. It should be noticed that the immune system does play critical roles in fighting viruses. Studies show that T cells levels decreased continuously as the disease progressed. T cell-mediated cellular immune response, probably by immunological memory, is essential for direct virus eradication after infection whilst B cells functions in producing antibodies that neutralize virus.But, have distinct patterns of T cell response exist in different patients, suggesting the possibility of distinct clinical approaches. Efforts are concentrated to elucidate the underlying immunological mechanisms in SARS-CoV-2 pathogenesis and progression for better design of diagnostic, therapeutic and preventive strategies. We seek to identify biomolecules with the potential to act in biomarkers that predict how severe the disease can get. But it is important to warn that the plants that produce the compounds mentioned here should not be used without a physician prescription. Finally, we speculate that these compounds may eventually attract the attention of physicians and researchers to perform tests in specific contexts of SARS-CoV-2 infection, and if they show positive results, be tested in Clinical trials.</p></sec></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>SARS-CoV-2</kwd><kwd>targets</kwd><kwd>medicinal plants</kwd><kwd>compounds</kwd><kwd>therapeutic effects</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Coordination of Improvement of Higher Education Personnel - Brazil (CAPES)</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100002322</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution>National Council for Scientific and Technological Development (CNPq)</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100003593</institution-id></institution-wrap></funding-source></award-group><funding-statement>This study was financed in part by the Coordination of Improvement of Higher Education Personnel - Brazil (CAPES) - Finance Code 001 and National Council for Scientific and Technological Development (CNPq).</funding-statement></funding-group></support-group><counts><fig-count count="3"/><table-count count="1"/><ref-count count="94"/><page-count count="11"/></counts></article-meta></front><body><sec id="s0001" disp-level="1"><label>1.</label><title>Introduction</title><p>The COVID-19 pandemic is a delicate global challenge that is demanding a paradigm shift [<xref rid="cit0001" ref-type="bibr">1</xref>]. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is extended to every continent, forcing us to adapt and live with this virus for perhaps a long time. Scientists quickly learned much about coronavirus disease and its pathogenesis [<xref rid="cit0002" ref-type="bibr">2</xref>]. SARS-CoV-2 has four main structural proteins: small envelope (E) glycoprotein, membrane (M) glycoprotein, nucleocapsid (N) protein, and spike (S) glycoprotein. S glycoprotein facilitates binding to host cells with angiotensin-converting enzyme 2 (ACE2) expressed in lower respiratory tract cells [<xref rid="cit0003" ref-type="bibr">3</xref>]. After the virus enters the host cell, SARS-CoV-2 binds to the ACE2 receiver, highly expressed in the lower respiratory tract. These include type II alveolar cells (AT2) of the lungs, esophagus, stratified epithelial cells, myocardial cells, and kidney proximal tubule cells. Therefore, patients who are infected with this virus experience not only respiratory problems such as pneumonia leading to acute respiratory distress syndrome (ARDS) but also heart, kidneys, and digestive tract disorders [<xref rid="cit0004" ref-type="bibr">4</xref>].</p><p>Much of the discussion about SARS-CoV-2 immunity has focused on antibodies. However, T cells target already infected cells and eradicate them, preventing viruses from spreading to other healthy cells. That is, while antibodies destroy viruses, T cells destroy cells in the body that have become &#x02018;virus factories&#x02019; [<xref rid="cit0005" ref-type="bibr">5</xref>]. In this sense, researchers are testing interleukin 7, a cytokine known to increase T cells&#x02019; production. This will serve to detect if the cells can really help in the recovery of patients infected with SARS-CoV-2 [<xref rid="cit0006" ref-type="bibr">6</xref>].</p><p>Even though vaccines have recently been approved, scientists keeping working to develop a treatment&#x02019;s [<xref rid="cit0007" ref-type="bibr">7</xref>]. Researchers have found 27 essential proteins in the blood of people infected with SARS-CoV-2 that can act as biomarkers that predict how severe the disease can get. They include complement factors, the coagulation system, inflammation modulators, and pro-inflammatory factors upstream and downstream as interleukin 6 (IL-6). The study reveals that these proteins are present at different levels in SARS-CoV-2 patients, depending on severity of their symptoms [<xref rid="cit0001" ref-type="bibr">1</xref>], which may provide new goals for developing possible treatments for the disease.</p><p>In this sense, considering the huge metabolic potential, plants appear as an important alternative in the search for potential compounds to fight this disease [<xref rid="cit0008" ref-type="bibr">8</xref>]. Based on their antiviral and anti-inflammatory effects, some phytochemicals such isoflavones, curcumin and diallyl disulfide, have attracted particular attention to providing novel agents in combating coronaviruses and related complications [<xref rid="cit0009" ref-type="bibr">9</xref>]. These compounds exert antiviral activities against broad spectrum of viruses including adenovirus, Zika virus, herpes simplex virus type 2 (HSV-2), human papiloma virus (HPV), influenza virus, hepatitis virus, and human immunodeficiency virus (HIV), besides MERS-CoV and SARS-CoV [<xref rid="cit0010" ref-type="bibr">10&#x02013;12</xref>]. The Brazilian Ministry of Health, 12&#x000a0;herbal medicines derived from plants that are part of the National List of Medicinal Plants of Interest to the Unified Health System (RENISUS), are available for free in the public health network [<xref rid="cit0013" ref-type="bibr">13</xref>]. The list includes 71 species of plants, some native to Brazil, however, most are exotic species, that are easily grown and used in other countries, often in the form of food or spices, such as garlic, saffron, soybeans, and ginger, for example [<xref rid="cit0014" ref-type="bibr">14</xref>]. It is noteworthy that many plants of the RENISUS list have already been researched concerning therapeutic effects or as adjuvants for different pathologies [<xref rid="cit0015" ref-type="bibr">15&#x02013;17</xref>]. In this sense, this review seeks to gather a summary of the information on compounds from RENISUS plants with properties to act in potential biomarkers related to SARS-CoV-2.</p></sec><sec id="s0002" disp-level="1"><label>2.</label><title>Methodology</title><sec id="s0002-s2001" disp-level="2"><label>2.1.</label><title>Search strategy</title><p>This systematic review focused on compounds of RENISUS plants with therapeutic properties to combat some SARS-CoV-2 targets. The studies of interest are indexed in MEDLINE/PubMed database. Thus, the scientific names of the 71 plants on the RENISUS list were used as the main search terms, along with the 27 potential biomarkers expressed in SARS-CoV-2 patients [<xref rid="cit0001" ref-type="bibr">1</xref>]: (alpha-1B-glycoprotein (A1BG), beta and gamma-1 actin (ACTB, ACTG1), albumin (ALB), apolipoprotein A-I (APO A-I), complement C1r (C1R), complement C1s (C1S), complement C8 alpha chain (C8A), cluster of differentiation 14 (CD14), complement factor B (CFB), complement factor H (CFH), complement factor I (CFI), C-reactive protein (CRP), fibrinogen alpha chain (FGA), fibrinogen beta chain (FGB), fibrinogen gamma chain (FGG), inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3), inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), lipopolysaccharide-binding protein (LBP), galectin 3-binding protein (LGALS3BP), leucine-rich alpha-2-glycoprotein (LRG1), serum amyloid A1 (SAA1), serum amyloid A2 (SAA2), haptoglobin (HP), apolipoprotein C1 (APOC1), gelsolin (GSN), transferrin (TF), protein Z-dependent protease inhibitor (SERPINA10), besides SARS-CoV-2, COVID-19, coronavirus, spike protein; angiotensin-converting enzyme 2 (ACE2), interleukin 7, and T cells.</p><p>Two reviewers were responsible for searching for publications and analyzing and interpreting the data to carry out this systematic review. All texts with full and open access, regardless of language, published until June 2020, were considered in all stages of the research. The Guideline of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used to design this systematic review (<xref ref-type="fig" rid="f0001">Figure 1</xref>). The Plant List (TPL) was used to verify the names of species.
<fig id="f0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>PRISMA flow diagram of the literature search and study selection process</p></caption><graphic content-type="black-white" xlink:href="IERJ_A_1903317_F0001_B"/></fig></p></sec><sec id="s0002-s2002" disp-level="2"><label>2.2.</label><title>Inclusion and exclusion criteria</title><p>To be considered in this review, studies had to meet the following criteria: preclinical studies or clinical trials (stage one); therapeutic evidence of the compound (stage two); therapeutic effects of the compounds against determined SARS-CoV-2 targets in preclinical (except <italic>in vitro</italic> studies) or clinical trials (stage three). Reviews, <italic>&#x02018;in vitro&#x02019;</italic> studies, semi structured interviews, commentaries, guideline articles, and research with mixtures of compounds were not computed. Duplicated studies were also excluded at the initial stage. After analyzing the abstract in stage two, the research that did not have therapeutic evidence of the compound was excluded. Studies that were not elected in stage three were excluded due to the lack of therapeutic evidence front SARS-CoV-2 targets analyzed in their entirety. As limitations, risk of bias was considered (e.g. publication bias, as duplicated papers, and &#x02018;<italic>in vitro</italic>&#x02019; studies are not considered; limitation of results found are limited as they are restricted to one database, besides the presence or absence of the keywords used and by the addition of other targets).</p></sec></sec><sec id="s0003" disp-level="1"><label>3.</label><title>Results</title><p>There are few results in the database using the plants&#x02019; scientific names together with the terms &#x02018;SARS-CoV-2,&#x02019; &#x02018;COVID-19,&#x02019; and &#x02018;coronavirus,&#x02019; being that none with therapeutic results so far. In this sense, <xref rid="t0001" ref-type="table">Table 1</xref> presents the results found with compounds from RENISUS plants with properties to act in potential biomarkers related to SARS-CoV-2.
<table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Selected scientific articles of compounds with therapeutic potential for SARS-CoV-2 targets</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*" align="left"/><col width="1*" align="left"/><col width="1*" align="left"/></colgroup><thead><tr><th align="left">Compound/concentration</th><th align="center">Main results</th><th align="center">Type of<break/>study</th></tr></thead><tbody><tr><td align="left">Flavonoid artemetin (0.75 and 1.5 mg/kg) (<italic toggle="yes">Achillea millefolium</italic> L. &#x02013; Asteraceae)</td><td align="left">Intravenous injection of artemetin in anesthetized rats significantly reduced the hypertensive response to angiotensin I. Artemetin (1.5 mg/kg) was also able to reduce plasma (37%) and vascular (63%) angiotensin-converting enzyme (ACE) activity. These effects may be associated of ability to decrease angiotensin II generation <italic toggle="yes">in vivo</italic>, by ACE inhibition</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0039">39</xref>]</td></tr><tr><td align="left">Allyl disulfide and alyl trisulfide/concentration not informed (<italic toggle="yes">Allium sativum</italic> L. &#x02013; Amaryllidaceae)</td><td align="left">Organosulfur compounds found in garlic essential oil have inhibitory effect in amino acids of the ACE2 protein and the main protease PDB6LU7 of SARS-CoV-2</td><td align="left">Molecular docking [<xref ref-type="bibr" rid="cit0040">40</xref>]</td></tr><tr><td align="left">Allicin (15, 30 and 45 mg &#x000b7; kg-1 &#x000b7; day-1) via daily intra-gastric gavage for 12&#x000a0;weeks (<italic toggle="yes">A. sativum</italic>)</td><td align="left">In streptozotocin (STZ)-induced diabetic rats, allicin reversed the albuminuria STZ-induced diabetic rats</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0044">44</xref>]</td></tr><tr><td align="left">1% high cholesterol diet (HCD) plus allicin (10 mg/kg/day) for 4&#x000a0;weeks (<italic toggle="yes">A. sativum</italic>)</td><td align="left">In rabbits, allicin supplementation significantly decreased serum CRP and significantly protected against HCD-induced attenuation of rabbit aortic</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0051">51</xref>]</td></tr><tr><td align="left">Diallyl sulfide (DAS) and diallyl disulfide (DADS) (200&#x000a0;&#x000b5;M was administrated twice orally with an interval of 12 h) for 5 consecutive days (<italic toggle="yes">A. sativum</italic>)</td><td align="left">DAS or DADS given twice significantly decreased the plasma levels of IL-6 and significantly reduced the plasma levels of C-reactive protein (CRP) in diabetic mice</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0036">36</xref>]</td></tr><tr><td align="left">DAS (100 mg/kg) was orally administered for 4&#x000a0;days (<italic toggle="yes">A. sativum</italic>)</td><td align="left">DAS afforded renal and neuroprotection against cyclophosphamide (CP)-induced nephropathic encephalopathy in rats due to its capacity to significantly decrease CRP and IL-6 levels</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0052">52</xref>]</td></tr><tr><td align="left">The intraperitoneally injected with 1 mL of CSE on days 1, 8, and 15 along with the daily injection of DADS (100 and 10 mg/kg/day) for 21&#x000a0;days (<italic toggle="yes">A. sativum</italic>)</td><td align="left">In rat emphysema model by intraperitoneal injection of cigarette smoke extract (CSE), DADS exerted an anti-inflammation effect on emphysema rats through suppressing IL-6 cytokine production. Furthermore, the regulation effects of DADS on CD4&#x0207a; and CD8&#x0207a; T cells were observed</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0037">37</xref>]</td></tr><tr><td align="left">13 mL of rapeseed oil enriched with 0.23 mL DADS (100&#x000a0;mmol/L) intragastrically (<italic toggle="yes">A. sativum</italic>)</td><td align="left">Stimulation of ferritin at the RNA and protein levels was found in rats administered a DADS-enriched oil solution. The expression of the transferrin receptor, an iron transporter, was also enhanced by DADS in rat liver</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0038">38</xref>]</td></tr><tr><td align="left">S-allycysteine (SAC) was administered orally (150 mg/kg b.w/rat) for 45&#x000a0;days (<italic toggle="yes">A. sativum</italic>)</td><td align="left">The levels of albumin were increased in SAC treated diabetic rats</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0045">45</xref>]</td></tr><tr><td align="left">SAC (150 mg/kg b.w/rat) in aqueous solution orally for 45&#x000a0;days (<italic toggle="yes">A. sativum</italic>)</td><td align="left">The levels of transferrin in tissues were increased in SAC-treated STZ-induced diabetic rats, suggest that SAC could have a protective effect against alterations in oxidative stress induced iron metabolism in the diabetic state</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0056">56</xref>]</td></tr><tr><td align="left">Two intraperitoneally injections of aloe-emodin&#x000a0;(50 mg/kg; CCl4+&#x000a0;aloe-emodin) (<italic toggle="yes">Aloe vera</italic> L. &#x02013; Asphodelaceae)</td><td align="left">In a rat model of carbon tetrachloride (CCl4) intoxication six rats treated with aloe-emodin, albumin mRNA expression was significantly lower only in the liver of CCl4 rats</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0046">46</xref>]</td></tr><tr><td align="left">Cytopiloyne at 25&#x000a0;&#x000b5;g/kg body weight three times per week (<italic toggle="yes">Bidens pilosa</italic> L. &#x02013; Asteraceae)</td><td align="left">Cytopiloyne promotes the differentiation of type 2&#x000a0;Th cells, which is consistent with it enhancing GATA-3 transcription. Also, does not compromise total antibodies (Ab) responses mediated by T cells in female NOD mice</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0057">57</xref>]</td></tr><tr><td align="left">Centaurein (75&#x000a0;&#x000b5;g/ml) (<italic toggle="yes">B. pilosa</italic>)</td><td align="left">Centaurein regulated IFN-gamma (IFN-&#x003b3;) transcription, probably via Nuclear factor of activated T-cells (NFAT) and factor nuclear kappa B (NF-kB) in T cells</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0058">58</xref>]</td></tr><tr><td align="left">C57BL/6&#x000a0;J mice were intraperitoneally injected with centaurein at 20&#x000a0;&#x003bc;g (<italic toggle="yes">B. pilosa</italic>)</td><td align="left">Centaurein increased the IFN-&#x003b3; expression in T and NK cells and the serum IFN-&#x003b3; level in mice. Centaurein elevated the transcription of T-bet which is consistent with its effect on that of IFN-&#x003b3;</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0059">59</xref>]</td></tr><tr><td align="left">C1 (1E,6E)-1,2,6,7-tetrahydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl) hepta-1,6-diene-3,5-dione) and C2 (4Z,6E)-1,5-dihydroxy-1,7-bis(4-hydroxyphenyl) hepta-4,6-dien-3-one (<italic toggle="yes">Curcuma longa</italic> L. &#x02013; Zingiberaceae)</td><td align="left">Compounds C1 and C2 showed minimum binding score (&#x02212;9.08 and &#x02212;8.07 kcal/mole) against Mpro protein (protease (Mpro) of the SARS-CoV2). These two compounds strongly bind to the catalytic core of the Mpro protein with higher efficacy than lopinavir, a standard antiretroviral of the protease inhibitor class</td><td align="left">X-ray crystallographic structure [<xref ref-type="bibr" rid="cit0067">67</xref>]</td></tr><tr><td align="left">Bioavailable curcumin diet (protein 34.2%, fat 16.5%, starch 28%, Bio-curcumin (BCM-95; Frutarom, Londerzeel, Belgium) 0.09% diet) (<italic toggle="yes">C. longa</italic>)</td><td align="left">Eight obese cats were fed to diet for two 8-week periods (cross-over study design) while maintaining animals in an obese state. Curcumin resulted in lower plasma &#x003b1;1-acid glycoprotein (AGP) concentration but not changed haptoglobin levels</td><td align="left">Clinical trial [<xref ref-type="bibr" rid="cit0030">30</xref>]</td></tr><tr><td align="left">500 mg curcumin capsules (total: 1,000 mg) twice daily for 12&#x000a0;weeks (<italic toggle="yes">C. longa</italic>)</td><td align="left">In 34 &#x003b2;-thalassemia patients, curcumin treatment significantly reduced serum levels of nontransferrin bound iron (NTBI), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) and not affected the transferrin saturation</td><td align="left">Randomized controlled trial [<xref ref-type="bibr" rid="cit0031">31</xref>]</td></tr><tr><td align="left">1,500-mg curcumin daily for 10&#x000a0;weeks (<italic toggle="yes">C. longa</italic>)</td><td align="left">In 22 patients with Type 2 diabetes, curcumin treatment the mean concentration of high-sensitivity CRP besides serum concentrations of triglyceride decreased</td><td align="left">Randomized controlled trial [<xref ref-type="bibr" rid="cit0032">32</xref>]</td></tr><tr><td align="left">Curcuminoids (500 mg TID per oral; n =&#x000a0;45) for a period of 4&#x000a0;weeks (<italic toggle="yes">C. longa</italic>)</td><td align="left">Curcuminoids were significantly efficacious in modulating all assessed inflammatory mediators: IL-6, tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), CRP, calcitonin gene related peptide (CGRP), substance P and monocyte chemotactic protein-1 (MCP-1) in 45 male subjects who were suffering from chronic sulfur mustard-induced pulmonary complications</td><td align="left">Randomized controlled trial [<xref ref-type="bibr" rid="cit0053">53</xref>]</td></tr><tr><td align="left">Curcumin thrice a week at a dose level of 50 mg/kg b.w were administered for 9 consecutive weeks (<italic toggle="yes">C. longa</italic>)</td><td align="left">In 8 rats curcumin treatment effectively reduced the IL-6 and CRP levels in blood serum prevented the Benzo(a)pyrene-induced lung injury</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0033">33</xref>]</td></tr><tr><td align="left">500 mg (one capsule) of curcumin with each meal (three times/day after meal) for 16&#x000a0;weeks (<italic toggle="yes">C. longa</italic>)</td><td align="left">During the trial (4&#x000a0;months) in 23 patients with T2DM, the curcumin treatment significantly reversed albuminuria</td><td align="left">Randomized controlled trial [<xref ref-type="bibr" rid="cit0034">34</xref>]</td></tr><tr><td align="left">200&#x000a0;&#x000b5;g of curcumin was i.p. injected daily until day 6 (<italic toggle="yes">C. longa</italic>)</td><td align="left">In mice, curcumin significantly increased CXCR5&#x000a0;+&#x000a0;B-cell lymphoma 6+&#x000a0;TFH cells and CD95+&#x000a0;GL-7+&#x000a0;germinal center B cells in draining lymph nodes. Total Ab production as well as high affinity Immunoglobulin G (IgG1 and IgG2b) Ab production was induced</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0035">35</xref>]</td></tr><tr><td align="left">Tetrahydrocurcumin (THC) 120 mg/kg per day, and 1 kg of the AIN 93&#x000a0;G diet contained 800 mg of THC, day 0 to day 25 (<italic toggle="yes">C. longa</italic>)</td><td align="left">THC had beneficial effects on 13 asthmatic mice such pathological changes (eosinophils hyper-production), Th17 and T cell subsets and attenuating the Th2 response</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0060">60</xref>]</td></tr><tr><td align="left">Diet containing 1% curcumin until the end of the study (<italic toggle="yes">C. longa</italic>)</td><td align="left">In New Zealand Black/White F1 female mice starting at 18&#x000a0;weeks of age with lupus nephritis (LN), curcumin induced the protective effects at least in part by its interaction with regulatory T (Treg) cells</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0018">18</xref>]</td></tr><tr><td align="left">Trans-anethole (FEO) (130 mg/kg FEO, thrice weekly for 1&#x000a0;week, by rubbing on shaved rat dorsal area) (<italic toggle="yes">Foeniculum vulgare</italic> Mill. &#x02013; Apiaceae)</td><td align="left">In six rats, hepatic dysfunction study indicates promising significant amelioration of liver function reflected in ALT, AST, alkaline phosphatase (ALP), bilirubin, albumin plasma levels by FEO treatment</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0047">47</xref>]</td></tr><tr><td align="left">Trans-anethole (FEO) (36.4, 72.8 or 145.6 mg/kg) once per day for 7 consecutive days (<italic toggle="yes">F. vulgare</italic>)</td><td align="left">In acute lung injury (ALI)-bearing mice, FEO treatment eliminated LPS&#x02011;induced histopathological changes, decreased the number of inflammatory cells, and reduced in IL-17 mRNA expression. In addition, trans&#x02011;anethole increased IL-10 mRNA expression in lung tissues and resulted in a marked elevation in Treg cells and reduction in Th17 cells in spleen tissues</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0061">61</xref>]</td></tr><tr><td align="left">Pinitol (0.05%, P-I and 0.1% pinitol, P-II) for 10&#x000a0;weeks (<italic toggle="yes">Glycine max</italic> L. Merrill &#x02013; Fabaceae)</td><td align="left">Pinitol supplementation with a high cholesterol (HFHC) diet (10% coconut oil plus 0.2% cholesterol) in hamsters fed-high fat was very effective on the elevation of antiatherogenic factors, including plasma HDL-cholesterol, apolipoprotein A-I (APO A-I), adiponectin, and paraoxonase (PON) activity</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0066">66</xref>]</td></tr><tr><td align="left">56 mg isoflavones/day for 17 day each with a 25-day washout period between treatments (<italic toggle="yes">G. max</italic>)</td><td align="left">In 22 young healthy, normolipidemic subjects (5 men and 17 women) soy protein with intact phytoestrogens (contained 0.9 mg (3.5&#x000a0;&#x000b5;M) daidzein and 1.0 mg (3.7&#x000a0;&#x000b5;M) genistein) increases HDL-cholesterol and APO A-I concentrations</td><td align="left">Controlled trial [<xref ref-type="bibr" rid="cit0020">20</xref>]</td></tr><tr><td align="left">Isoflavone (80 mg day-1, n =&#x000a0;100) for 24&#x000a0;weeks (<italic toggle="yes">G. max</italic>)</td><td align="left">In patients with ischemic stroke isoflavone therapy caused a significant decrease in serum levels of CRP and IL-6 levels</td><td align="left">Randomized controlled trial [<xref ref-type="bibr" rid="cit0021">21</xref>]</td></tr><tr><td align="left">Isoflavone (80 mg/day, n =&#x000a0;50) for 12&#x000a0;weeks (<italic toggle="yes">G. max</italic>)</td><td align="left">In patients with prior ischemic stroke, isoflavone treatment resulted in a significant decrease in serum CRP levels and improved brachial flow-mediated dilatation in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status</td><td align="left">Randomized controlled trial [<xref ref-type="bibr" rid="cit0022">22</xref>]</td></tr><tr><td align="left">Soy isoflavones (genistein) 40 mg/day for 6&#x000a0;months (<italic toggle="yes">G. max</italic>)</td><td align="left">Genistein does not interfere in high-sensitive serum CRP levels in 20 healthy postmenopausal women</td><td align="left">Randomized controlled trial [<xref ref-type="bibr" rid="cit0023">23</xref>]</td></tr><tr><td align="left">Genistein (0.5, 1.0, or 2.0 mg (kg body mass) (&#x02212;1); by subcutaneous injection) for 8&#x000a0;weeks (<italic toggle="yes">G. max</italic>)</td><td align="left">In the liver injury induced in rats by thioacetamide revealed that the treatment of genistein decreased the elevated serum levels of AST, ALT and total and direct bilirubin, and increased the serum level of albumin</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0024">24</xref>]</td></tr><tr><td align="left">Genistein (300 mg/kg/day) was administered orally for 24&#x000a0;weeks (<italic toggle="yes">G. max</italic>)</td><td align="left">In streptozotocin STZ-induced diabetic rats, administration of genistein resulted in a decrease in blood glucose, % glycosylated hemoglobin (HbA1c), CRP and in augmentation of total antioxidant reserve of the hearts</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0025">25</xref>]</td></tr><tr><td align="left">Genistein (20 mg/kg) administered 10&#x000a0;days before to 10&#x000a0;days after the tumor induction (<italic toggle="yes">G. max</italic>)</td><td align="left">In adult female C57BL/6 mice, genistein significantly increased lymphocyte proliferation and LDH release. Furthermore, the treatment caused a significant increment in IFN-&#x003b3; levels and achieved significant therapeutic effect in tumor model of <italic toggle="yes">Human Papillomavirus</italic> (HPV) associated-cervical cancer</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0026">26</xref>]</td></tr><tr><td align="left">Active compound soybean ACE2 inhibitor (ACE2iSB) (<italic toggle="yes">G. max</italic>)</td><td align="left">ACE2iSB strongly inhibited recombinant human (rh)ACE2 activity with an IC<sub>50</sub> value of 84&#x000a0;nM. This is the first demonstration of an ACE2 inhibitor by HPLC-MS with fluorescence detection</td><td align="left">HPLC-MS [<xref ref-type="bibr" rid="cit0041">41</xref>]</td></tr><tr><td align="left">Daidzein (DAZ) at 10 mg/kg body weight dose by oral gavage daily for six weeks (<italic toggle="yes">G. max</italic>)</td><td align="left">Adult Balb/c mice treated with DAZ increased the percentage of CD4&#x0207a;CD28&#x0207a; T cells and DAZ also regulated B lymphopoesis</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0027">27</xref>]</td></tr><tr><td align="left">Orally administered DAZ at various physiological doses (2&#x02013;20 mg/kg body weight) during adulthood (<italic toggle="yes">G. max</italic>)</td><td align="left">DAZ in female B6C3F1 mice, the T cell populations (CD3+&#x000a0;IgM-, CD4+&#x000a0;CD8- and CD4-CD8+) were increased. The activities cytotoxic T cells and natural killer cells were not altered. In NOD mice, DAZ modulated the antibody production, as shown by increased levels of IgG2b and IgG1. DAZ increased CD8+&#x000a0;CD25+&#x000a0;splenocytes in NOD females</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0028">28</xref>]</td></tr><tr><td align="left">Intraperitoneally (IP) injection with lunasin at 0.4 or 4 mg/kg body weight (<italic toggle="yes">G. max</italic>)</td><td align="left">In BALB/c mice lunasin inhibited the growth of (OVA) ovalbumin-expressing A20 B-lymphomas, which was correlated with OVA-specific CD8&#x000a0;+&#x000a0;T cells. In addition, lunasin was an effective adjuvant for immunization with OVA, which together improved animal survival against lethal challenge with influenza virus expressing the major histocompatibility complex (MHC) class I OVA peptide SIINFEKL (PR8-OTI)</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0062">62</xref>]</td></tr><tr><td align="left">Equol 20 mg/kg for 3&#x000a0;days by gavage (<italic toggle="yes">G. max</italic>)</td><td align="left">In BALB/c mice treated with equol showed a significantly higher level of OVA-specific IgE. IL-13 (produced mainly by CD4&#x0207a; T cells) production level was significantly higher than that control</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0029">29</xref>]</td></tr><tr><td align="left">7S globulin (<italic toggle="yes">Momordica charantia</italic> L. &#x02013; Cucurbitaceae)</td><td align="left">Study revealed that a tripeptide (VFK) from 7S globulin possess a higher binding affinity for ACE than reported drug Lisinopril (LPR)</td><td align="left">Not mentioned [<xref ref-type="bibr" rid="cit0042">42</xref>]</td></tr><tr><td align="left">Lectin 100&#x000a0;&#x000b5;g/ml (<italic toggle="yes">M. charantia</italic>)</td><td align="left">Lectin is a T cell-independent B cell activator and a polyclonal immunoglobulin (Ig) inducer in BALB/c mice. Additionally, lectin was shown to upregulate the cell activation marker CD86, in a B cell subpopulation</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0063">63</xref>]</td></tr><tr><td align="left">MAP30 (anti-HIV protein) 1&#x000a0;&#x000b5;M (<italic toggle="yes">M. charantia</italic>)</td><td align="left">MAP30 was capable of inhibiting infection of HIV type 1 (HIV-1) in T lymphocytes and monocytes as well as replication of the virus in already-infected cells. Integration of viral DNA into the host chromosome is a vital step in the replicative cycle of retroviruses, including the AIDS virus. The inhibition of HIV-1 integrase by MAP30 suggests that impediment of viral DNA integration may play a key role in the anti-HIV activity</td><td align="left">Genomic studies [<xref ref-type="bibr" rid="cit0019">19</xref>]</td></tr><tr><td align="left">1-Deoxynojirimycin (DNJ) 10 mg daily for 4&#x000a0;weeks (<italic toggle="yes">Morus indica</italic> L. &#x02013; Moraceae)</td><td align="left">In 72 patients with with coronary heart disease (CHD) and blood stasis syndrome (BSS) DNJ significantly reduced the levels of CRP, IL-6, TNF-&#x003b1;, malondialdehyde (MDA), Self-Rating Anxiety Scale (SAS) and Hamilton Depression Scale (HAMD) and BSS scores and increased superoxide dismutase (SOD) levels</td><td align="left">Randomized controlled trial [<xref ref-type="bibr" rid="cit0054">54</xref>]</td></tr><tr><td align="left">Phyllanthin and hypophyllanthin (50, 100, and 200 mg/kg) for next 28 day (<italic toggle="yes">Phyllanthus amarus</italic> Schumach. &#x00026; Thonn. &#x02013; Euphorbiaceae)</td><td align="left">In Sprague Dawley rats by OVA-challenged, compounds significantly decreased the levels of albumin in serum, bronchoalveolar lavage fluid (BALF) and lungs. OVA-induced increase in IgE, oxidative-stress (SOD, GSH, MDA, NO, Nrf2 and iNOs), inflammatory makers (HO-1, TNF-&#x003b1;, IL-1&#x003b2; and IL-6) levels were significantly decreased by compounds</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0048">48</xref>]</td></tr><tr><td align="left">Geraniin 5 mg/kg was orally administered once (<italic toggle="yes">P. amarus</italic>)</td><td align="left">Spontaneously hypertensive rats, the geraniin showed antihypertensive activity in lowering systolic blood pressure and diastolic blood pressure. Geraniin also showed dose-dependent inhibitory activities against ACE (IC<sub>50</sub> were 13.22&#x000a0;&#x000b5;M)</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0043">43</xref>]</td></tr><tr><td align="left">(-)-Epicatechin&#x000a0;50 mg/kg body weight for 21&#x000a0;days (<italic toggle="yes">Phyllanthus niruri</italic> L. &#x02013; Euphorbiaceae)</td><td align="left">Albumin levels are depleted in hepatitic rats, (-)-epicatechin pretreatment increased albumin levels. Also, pretreatment decreased the tissue damage in hepatitis condition</td><td align="left">Pre-clinical&#x000a0;<italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0049">49</xref>]</td></tr><tr><td align="left">Punicalagin (10, 20, and 40 mg/kg/day, i.p.) for 11&#x000a0;days (<italic toggle="yes">Punica granatum</italic> L. &#x02013; Lythraceae)</td><td align="left">Acrylamide-induce toxicity in rat and decrease levels of serum protein and albumin concentration. Punicalagin recovered these levels</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0050">50</xref>]</td></tr><tr><td align="left">10-dehydrogingerdione&#x000a0;(10 mg/kg body weight orally, see isolation and purification) (<italic toggle="yes">Zingiber officinale</italic> Roscoe &#x02013; Zingiberaceae)</td><td align="left">Six New Zealand male rabbits 10-dehydrogingerdione-treated daily during the 6&#x000a0;weeks showed a significant improvement in serum lipids and this effect was correlated to its ability to lower high sensitivity C-reactive protein (hsCRP), homocysteine and matrix metalloproteinase 9 (MMP9) levels</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0055">55</xref>]</td></tr><tr><td align="left">Zerumbone (0.1, 1, and 10 mg/kg of body weight) orally fed from days 23 to 39 (<italic toggle="yes">Z. officinale</italic>)</td><td align="left">In BALB/c mice asthmatic model compared to OVA-induced hallmarks of asthma, zerumbone induced higher IgG2a antibody production and promoted Th1 cytokine IFN-&#x003b3; production</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0064">64</xref>]</td></tr><tr><td align="left">6-Gingerol (0.01%)-containing drinking water until the end of the experiments (100&#x000a0;days) (<italic toggle="yes">Z. officinale</italic>)</td><td align="left">In female Balb/c and C57BL/6 (8&#x02013;10 mice), 6-gingerol treatment caused massive infiltration of CD4 and CD8 T-cells and B220(+) B-cells, but reduced the number of CD4(+) Foxp3(+) regulatory T-cells</td><td align="left">Preclinical <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="cit0065">65</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Source</bold>: Research data, 2021.</p></fn></table-wrap-foot></table-wrap>
</p><p>The research found studies of interest with 14 plants from RENISUS list, two of them (<italic>A. vera</italic> and <italic>G. max</italic>) are available for free as herbal medicines in the Brazilian Health System (SUS) [<xref rid="cit0013" ref-type="bibr">13</xref>]. As the search for new treatments is urgent, the evaluation focuses on compounds and not plants or their extracts. Through this, the search selected studies with results against SARS-CoV-2 targets with 34 different compounds (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><p>The compounds with the highest concentration of studies are soy isoflavones (genistein, daidzein and equol) [<xref rid="cit0020" ref-type="bibr">20&#x02013;29</xref>], curcumin [<xref rid="cit0030" ref-type="bibr">30&#x02013;35</xref>] and diallyl disulfide [<xref rid="cit0036" ref-type="bibr">36&#x02013;38</xref>]. Among the 31 SARS-CoV-2 targets analyzed (<xref ref-type="fig" rid="f0002">Figure 2</xref><fig id="f0002" fig-type="figure" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Main activities of compounds against SARS-CoV-2 targets</p></caption><alternatives><graphic specific-use="web-only" content-type="color" xlink:href="IERJ_A_1903317_F0002_OC"/><graphic specific-use="print-only" content-type="black-white" xlink:href="IERJ_A_1903317_F0002_PB"/></alternatives></fig>
</p><p>), studies were found for ACE activity [<xref rid="cit0039" ref-type="bibr">39&#x02013;43</xref>], reverted serum albumin levels [<xref rid="cit0024" ref-type="bibr">24</xref>,<xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0044" ref-type="bibr">44&#x02013;50</xref>], decreased of the plasma levels of CRP [<xref rid="cit0021" ref-type="bibr">21&#x02013;23</xref>,<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0036" ref-type="bibr">36</xref>,<xref rid="cit0051" ref-type="bibr">51&#x02013;55</xref>], transferrin saturation [<xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0038" ref-type="bibr">38</xref>,<xref rid="cit0056" ref-type="bibr">56</xref>], T cells regulation [<xref rid="cit0025" ref-type="bibr">25&#x02013;29</xref>,<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0057" ref-type="bibr">57&#x02013;65</xref>], haptoglobin levels decreased [<xref rid="cit0030" ref-type="bibr">30</xref>], APO A-I concentrations decreased [<xref rid="cit0020" ref-type="bibr">20</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>]. Compounds of interest reversed these activities, but in contexts unrelated to SARS-CoV-2, except for two studies. One suggests the inhibitory effect of the compounds Allyl disulfide and Allyl trisulfide in amino acids of the ACE2 protein and the main protease PDB6LU7 of SARS-CoV-2 [<xref rid="cit0040" ref-type="bibr">40</xref>]. The other suggests a strong bind of two compounds of <italic>C. longa</italic> (C1 and C2) to the catalytic core of the Mpro protein (one of the main proteases of the SARS-CoV-2) [<xref rid="cit0067" ref-type="bibr">67</xref>]. In view of these results, <xref ref-type="fig" rid="f0003">Figure 3</xref> presents a scheme that summarizes these results with the aim to better understand the action of compounds against SARS-CoV-2.
<fig id="f0003" fig-type="figure" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Scheme of phytoconstituents action in SARS-CoV-2. <bold>(A)</bold> SARS-CoV-2 enters through oral and respiratory mucosal cells. <bold>(B)</bold> Inhibitor compounds block the binding of the spike protein to the ACE2 surface. <bold>(C)</bold> SARS-CoV-2 downregulates albumin levels. Compounds induce serum albumin levels regulation. Albumin induce the decreased expression of the ACE2 receptors. <bold>(D)</bold> Through the spike protein, SARS-CoV-2 binds to the ACE2 surface and enters the cell epithelium, where it will fuse with the vesicle and release its RNA in the nucleus to reproduce. The new copies of the virus will be detected by T cells induced by compounds that bind to the spike protein to fight the virus&#x02019;s action. <bold>(E)</bold> SARS-CoV-2 downregulates haptoglobin levels that induce thus, the presence of hemolysis. Compounds did not change haptoglobin levels. <bold>(F)</bold> SARS-CoV-2 induces increased CRP levels. Compounds decreased the plasma levels of CRP. <bold>(G)</bold> SARS-CoV-2 downregulates APO A-I levels. Compounds induce an increase in APO A-I concentrations</p></caption><alternatives><graphic specific-use="web-only" content-type="color" xlink:href="IERJ_A_1903317_F0003_OC"/><graphic specific-use="print-only" content-type="black-white" xlink:href="IERJ_A_1903317_F0003_PB"/></alternatives></fig>
</p></sec><sec id="s0004" disp-level="1"><label>4.</label><title>Discussion</title><p>The update by Newman and Cragg (2020) reports that, from the total number of new chemical entities (NCEs) released between 1981&#x02013;2019 (1,881), 53% are either a natural product or derived from one. From the 186 molecules discovered in this period about antiviral agents, 19% come from natural products and their derivatives. Many approved agents are vaccines, often directed against various influenza serotypes, as expected from the many flu outbreaks [<xref rid="cit0068" ref-type="bibr">68</xref>].</p><p>In a previous research, it was reported that traditional herbal remedies could help to improve symptoms, life&#x02010;quality, absorptions of pulmonary infiltrations, and decrease corticosteroids uses in SARS patients [<xref rid="cit0069" ref-type="bibr">69</xref>]. Some of the compounds suggested in this review with activity against SARS-CoV-2 targets are already described with antiviral properties. Garlic is known for its antiviral properties due to the activity of its compounds. For example, allyl disulfide strongly decreased cell proliferation of HIV-infected cells [<xref rid="cit0070" ref-type="bibr">70</xref>]. <italic>In vivo</italic> experiment with allicin, compound exhibited the antiviral activity against influenza viruses by improving the production of neutralizing antibodies when given to mice [<xref rid="cit0071" ref-type="bibr">71</xref>]. Moreover, DADS was effective against the human cytomegalovirus (HCMV) replication and viral immediate-early gene expression. It acts by enhancing NK-cells activity that destroys virus-infected cells [<xref rid="cit0072" ref-type="bibr">72</xref>]. Preclinical data show that all these antiviral activities of garlic and its active organosulfur compounds are related to cell signaling process, such, downregulating the extracellular-signal-regulated kinase (ERK)/mitogen activated protein kinase (MAPK) signaling pathway, block of viral entry into host cells, inhibition viral RNA polymerase, reverse transcriptase, as well as through DNA synthesis and immediate-early gene 1 (IEG1) transcription. Also, clinical trials further demonstrated a prophylactic effect of garlic in the prevention of viral infections through enhancing the immune response [<xref rid="cit0073" ref-type="bibr">73</xref>]. In this review, we found a study that indicates the regulation effects of DADS on CD4&#x0207a; and CD8&#x0207a; T cells [<xref rid="cit0037" ref-type="bibr">37</xref>]. Another compound with well-established antiviral properties is curcumin. An <italic>in vivo</italic> study on a mouse model with intravaginal HSV-2 showed significant protection against HSV-2 infection due to curcumin administration [<xref rid="cit0074" ref-type="bibr">74</xref>]. Curcumin exerts its antiviral effects through signaling pathways, such as actin filament organization by replication inhibition in dengue virus and viral hemorrhagic septicemia virus; anti-inflammation and antioxidation activity inhibiting HIV replication; conformation of viral/cellular surface proteins through viral attachment in Zika virus, chikungunya virus, vesicular stomatitis virus, and human respiratory syncytial virus; HSC71 expression induces viral entry block in viral hemorrhagic septicemia virus; NF-&#x003ba;B signaling induce inhibition the replication and viral egress in Influenza A virus and HSV-2 [<xref rid="cit0075" ref-type="bibr">75</xref>]. We found nine surveys showing curcumin activity against SARS-CoV-2 targets. According to this review, curcumin did not affect the transferrin saturation [<xref rid="cit0031" ref-type="bibr">31</xref>], induced an increase in the regulation of T cells [<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0060" ref-type="bibr">60</xref>], decreased the mean concentration of CRP protein [<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0053" ref-type="bibr">53</xref>], and reverted albuminuria levels [<xref rid="cit0034" ref-type="bibr">34</xref>], and did not change haptoglobin levels [<xref rid="cit0030" ref-type="bibr">30</xref>]. Haptoglobin, an acute-phase protein, is produced by hepatocytes and, also by lung epithelial cells. Its levels decrease in patients with SARS-CoV-2 and indicate the presence of hemolysis within the body (<xref ref-type="fig" rid="f0003">Figure 3E</xref>). Haptoglobin reduces bronchial hyperreactivity [<xref rid="cit0076" ref-type="bibr">76</xref>]. In parallel, as both the host and pathogen require iron, the innate immune response seeks to control iron metabolism to limit its availability during infection. In patients with SARS-CoV-2, low transferrin saturation is observed because many viruses use the transferrin receptor to enter cells [<xref rid="cit0077" ref-type="bibr">77</xref>].</p><p>The different isoflavones exert antiviral properties against a wide range of viruses. The mechanisms of antiviral action of isoflavones have not been fully elucidated, but current results suggest a combination of effects on both the virus and the host cell. It is described that isoflavones to affect virus binding, entry, replication, viral protein translation and formation of certain virus envelope glycoprotein complexes. Also tamper in a variety of host cell signaling processes, including induction of gene transcription factors and secretion of cytokines [<xref rid="cit0011" ref-type="bibr">11</xref>]. Genistein is the most studied soy isoflavone in this regard. It has been shown to inhibit the infectivity of various viruses affecting humans and animals, including adenovirus, herpes simplex virus, HIV, respiratory syndrome virus, and rotavirus [<xref rid="cit0011" ref-type="bibr">11</xref>], besides against a previous coronavirus strain (SARS-CoV). In this review, <italic>in vivo</italic> studies indicate that administration of genistein resulted in a decrease in CRP levels [<xref rid="cit0025" ref-type="bibr">25</xref>], modulated an increase in T cells (lymphocyte proliferation) and a significant increment in IFN-&#x003b3; levels that showed a significant therapeutic effect in a tumor model of HPV [<xref rid="cit0022" ref-type="bibr">22</xref>]. Besides, it increased APO A-I concentrations in young, healthy people [<xref rid="cit0020" ref-type="bibr">20</xref>], and induces an increase in serum level of albumin [<xref rid="cit0024" ref-type="bibr">24</xref>]. Researchers who studied the clinical characteristics of SARS-CoV-2 patients have reported that lower serum albumin levels were associated with an increased risk of death [<xref rid="cit0078" ref-type="bibr">78</xref>]. Also, albumin downregulates the expression of the ACE2 receptors and has been shown to improve the ratio of the partial pressure arterial oxygen and fraction of inspired oxygen in patients (<xref ref-type="fig" rid="f0003">Figure 3C</xref>) [<xref rid="cit0079" ref-type="bibr">79</xref>]. In this review was found one research that suggests serum albumin levels regulation by aloe-emodin action [<xref rid="cit0046" ref-type="bibr">46</xref>], which is a biologically active component of <italic>A. vera</italic>, and this compound has previously shown potential for SARS-CoV-2. Phenolics such as aloe-emodin, hesperetin, quercetin, naringenin, emodin, and chrysophanol were examined for their capacity against cleavage of the SARS-CoV 3&#x000a0;CLpro. Study showed that aloe-emodin and hesperetin were able to block cleavage of SARS-CoV 3CLpro dose-dependently manner [<xref rid="cit0080" ref-type="bibr">80</xref>]. Another important factor is that the increased level of plasma CRP was positively correlated to the severity of COVID-19 pneumonia (<xref ref-type="fig" rid="f0003">Figure 3F</xref>). Clinically, increased CRP levels might be early indicators of infections in SARS-CoV-2 patients who had a slow recovery and might aid physicians to administer antibiotics treatment early [<xref rid="cit0081" ref-type="bibr">81</xref>]. It is also known that APO A-I is the largest component of the HDL particle, considered as a marker of cardiovascular risk. In this sense, a low serum level of apolipoprotein A1 is an indicator of severity in SARS-CoV-2 patients (<xref ref-type="fig" rid="f0003">Figure 3G</xref>) [<xref rid="cit0082" ref-type="bibr">82</xref>]. Many patients have underlying cardiovascular disease (CVD) or develop acute cardiac injury during the infection. Acute cardiac injury, defined as a significant elevation of cardiac troponins, is the most reported cardiac abnormality in SARS-CoV-2 [<xref rid="cit0083" ref-type="bibr">83</xref>].</p><p>There are several vaccines under study, and some have already been approved by regulatory agencies. Two vaccines published the results of phase III of the study with more 90% of effectiveness. Both studies showed that the vaccines are safe and induced the immune response by T cell activity [<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0085" ref-type="bibr">85</xref>]. In our review, the compounds DADS [<xref rid="cit0037" ref-type="bibr">37</xref>], cytopiloyne [<xref rid="cit0057" ref-type="bibr">57</xref>], centaurein [<xref rid="cit0058" ref-type="bibr">58</xref>,<xref rid="cit0059" ref-type="bibr">59</xref>], curcumin [<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0060" ref-type="bibr">60</xref>], trans-anethole [<xref rid="cit0061" ref-type="bibr">61</xref>], daidzein isoflavone [<xref rid="cit0027" ref-type="bibr">27</xref>,<xref rid="cit0028" ref-type="bibr">28</xref>], genistein [<xref rid="cit0026" ref-type="bibr">26</xref>], equol isoflavone [<xref rid="cit0029" ref-type="bibr">29</xref>], zerumbone [<xref rid="cit0064" ref-type="bibr">64</xref>], 6-Gingerol [<xref rid="cit0065" ref-type="bibr">65</xref>], lectin [<xref rid="cit0063" ref-type="bibr">63</xref>], and lunasin [<xref rid="cit0062" ref-type="bibr">62</xref>] stimulate T cell responses (<xref ref-type="fig" rid="f0003">Figure 3D</xref>). Lectin has previously show effective against influenza virus [<xref rid="cit0086" ref-type="bibr">86</xref>], and peptide lunasin, for example, in BALB/c mice, improved survival in infected animals with the influenza virus, which suggests that lunasin can promote dendritic cells (DCs) maturation, increasing the development of protective immune responses to the vaccine antigens [<xref rid="cit0062" ref-type="bibr">62</xref>]. U.S. researchers demonstrated that both CD4 +&#x000a0;and CD8&#x000a0;+&#x000a0;T lymphocytes were able to recognize proteins not only Spike protein but also other proteins from SARS-CoV-2. When found these peptides, T cells were activated and produced cytokines, a sign that recognition was functional [<xref rid="cit0087" ref-type="bibr">87</xref>]. Swedish researchers analyzed frozen T cells from blood donors who donated in 2019 (before the pandemic) and after the start in 2020. Assessing the frequency of T cells capable of activating by recognizing the viral peptide megapool, the researchers demonstrated that this recognition was rare in blood donor cells in 2019, but relatively frequent in individuals who donated in 2020, suggesting prior contact with the virus that may have resulted in specific T cells. But the curious fact was that most of the individuals who lived with infected patients had a relatively high frequency of T cells recognizing megapool peptides, suggesting that these exposed individuals had generated T responses against the virus (potentially protective) even though they were asymptomatic [<xref rid="cit0088" ref-type="bibr">88</xref>]. These individuals are presumed to have T cells capable of recognizing SARS-CoV-2 even before encountering the virus. This hypothesis is based on the concept that similar pathogens (SARS-CoV or other influenza viruses such as influenza) often have equal portions of proteins, and a T response against a peptide derived from a protein with identical sequence in different pathogens can lead to a cross recognition [<xref rid="cit0089" ref-type="bibr">89</xref>]. This cross-recognition with other coronaviruses was exactly what other recent papers have shown. The data from these studies indicate that the S, N, NSP3, NSP4, ORF3a, ORF8, NSP7, NSP13 and probably other proteins from SARS-CoV-2 are recognized when peptides are used to stimulate T cells of individuals never exposed to SARS- CoV-2 [<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0091" ref-type="bibr">91</xref>]. In this sense, it is imagined that preexisting T cells could limit the intensity of the infection or even prevent the patient from becoming seriously ill when exposed to the new coronavirus. There is also the possibility that having a previous T response may be harmful and that preexisting anti-SARS-CoV-2 cells may cause further inflammation and increase the severity of the disease. However, there is no evidence to pinpoint this T-cell pre-response as potentially harmful. The most likely hypothesis, therefore, is that of protection, even if partial [<xref rid="cit0092" ref-type="bibr">92</xref>].</p><p>This cross recognition is a hope now that COVID-19 has entered perilous phase, because after initially containing SARS-CoV-2 infection, many countries had a resurgence of COVID-19 levels consistent with a large proportion of the population remaining susceptible to the virus after the first epidemic wave. This is due to new variants of the virus, such as the strain of Brazil, first discovered in Manaus, and which spread rapidly with rates up to 10 times higher in virulence, impacting on greater contagion and consequently higher mortality rate, also due to the low vaccination rate so far in countries like Brazil [<xref rid="cit0093" ref-type="bibr">93</xref>]. Finally, it should be noted that each study of interest in this review points out the compounds&#x02019; activity generally for a selected target. However, it is important to emphasize that the therapeutic approach for SARS-CoV-2 is broader and more complex. Our approach focused on a specific group of compounds and SARS-CoV-2 targets that may be the product of reactions caused by infection, but there are hundreds of other compounds with potential besides genes related to COVID-19 being analyzed [<xref rid="cit0094" ref-type="bibr">94</xref>].</p></sec><sec id="s0005" disp-level="1"><label>5.</label><title>Conclusion</title><p>Even though vaccines are being developed, new therapeutic alternatives for SARS-CoV-2 are essential, since compounds extracted from plants present a diverse range of therapeutic activities, including antiviral properties that may be beneficial to act on SARS-CoV-2 targets. The direct benefit of most of these compounds is that their effects on the human body and their safety are already established through clinical trials for another diseases. However, as most of the studies selected in this review did not evaluate the direct compounds&#x02019; behavior against SARS-CoV-2, the compounds need to be tested under specific SARS-CoV-2 conditions. Thus, utmost care is required while prescribing the phytocompounds as their uncontrolled use can have long-term side effects on the patient&#x02019;s body. In this sense, the search for new substances makes it possible to find &#x02018;old compounds&#x02019; with new mechanisms of action or reveal new functional groups. We hope this compilation will help researchers and clinicians to identify the appropriate antiviral compounds for combating COVID-19 and contribute to save millions of human lives.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the University of Taquari Valley, Brazil.</p></ack><sec id="s0006" disp-level="1"><title>Declaration of interest</title><p>The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</p></sec><sec id="s0007" disp-level="1"><title>Reviewer disclosures</title><p>Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.</p></sec><sec id="s0008" disp-level="1"><title>Article Highlights</title><p><list list-type="bullet"><list-item><p>Researchers have found essential proteins in the blood of people infected with SARS-CoV-2 that can act as biomarkers that predict how severe the disease can get.</p></list-item><list-item><p>Most of the studies selected in this review did not evaluate the direct compounds&#x02019; behavior against SARS-CoV-2.</p></list-item><list-item><p>Care is required while prescribing phytocompounds as their uncontrolled use can have long-term side effects.</p></list-item><list-item><p>The immune-modulatory effect makes T cells a potential tool for the antiviral drug-discovery.</p></list-item><list-item><p>The compounds offer therapeutic options to fight the SARS-CoV-2 infection.</p></list-item></list></p></sec><ref-list><title>References</title><p>Papers of special note have been highlighted as either of interest (&#x02022;) or of considerable interest (&#x02022;&#x02022;) to readers.</p><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Messner</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Demichev</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Wendisch</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection</article-title>. <source>Cell Syst</source> . <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>24</lpage>. <comment>e4</comment>.<pub-id pub-id-type="pmid">32619549</pub-id></mixed-citation><note><p><bold>&#x02022;&#x02022; This paper guides the conduct of this review because it shows proteins (targets) that are present at different levels in SARS-CoV-2 patients, depending on severity of their symptoms.</bold></p></note></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guan</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Ni</surname>
<given-names>ZY</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>18</issue>):<fpage>1708</fpage>&#x02013;<lpage>1720</lpage>.<pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hillyer</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>L.</given-names></string-name></person-group>
<article-title>Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses</article-title>. <source>Trends Immunol</source>. <year>2020</year>;<volume>41</volume>(<issue>6</issue>):<fpage>545</fpage>.<pub-id pub-id-type="pmid">32362491</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zhong</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Deng</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa</article-title>. <source>Int J Oral Sci</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">31900382</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vardhana</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Wolchok</surname>
<given-names>JD</given-names></string-name></person-group>. <article-title>The many faces of the anti-COVID immune response</article-title>. <source>J Exp Med</source>. <year>2020</year>;<volume>217</volume>(<issue>6</issue>):<fpage>e20200678</fpage>.<pub-id pub-id-type="pmid">32353870</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jamilloux</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Henry</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Belot</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions</article-title>. <source>Autoimmun Rev</source>. <year>2020</year>;<volume>19</volume>(<issue>7</issue>):<fpage>102567</fpage>.<pub-id pub-id-type="pmid">32376392</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Updated approaches against SARS-CoV-2</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>(<issue>6</issue>):<fpage>e00483</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">32205349</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vellingiria</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Jayaramayya</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Iyer</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>COVID-19: a promising cure for the global panic</article-title>. <source>Sci Total Environ</source>. <year>2020</year>;<volume>725</volume>:<fpage>138277</fpage>.<pub-id pub-id-type="pmid">32278175</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Majnooni</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Fakhri</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shokoohinia</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Phytochemicals: potential therapeutic interventions against coronavirus-associated lung injury</article-title>. <source>Front Pharmacol</source>. <year>2020</year>;<volume>11</volume>:<fpage>588467</fpage>.<pub-id pub-id-type="pmid">33658931</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rajendran</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shah</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV</article-title>. <source>J Biomol Struct Dyn</source>. <year>2021</year>;<fpage>1</fpage>&#x02013;<lpage>9</lpage>. DOI:<pub-id pub-id-type="doi">10.1080/07391102.2020.1868338</pub-id>.</mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andres</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Donovan</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Kuhlenschmidt</surname>
<given-names>MS</given-names></string-name></person-group>. <article-title>Soy isoflavones and virus infections</article-title>. <source>J Nutr Biochem</source>. <year>2009</year>;<volume>20</volume>(<issue>8</issue>):<fpage>563</fpage>&#x02013;<lpage>569</lpage>.<pub-id pub-id-type="pmid">19596314</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rao</surname>
<given-names>PSS</given-names></string-name>, <string-name><surname>Midde</surname>
<given-names>NM</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>DD</given-names></string-name>, et al</person-group>. <article-title>Diallyl sulfide: potential use in novel therapeutic interventions in alcohol, drugs, and disease mediated cellular toxicity by targeting cytochrome P450 2E1</article-title>. <source>Curr Drug Metab</source>. <year>2015</year>;<volume>16</volume>(<issue>6</issue>):<fpage>486</fpage>&#x02013;<lpage>503</lpage>.<pub-id pub-id-type="pmid">26264202</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Brazil</collab></person-group>. <article-title>Minist&#x000e9;rio da Sa&#x000fa;de. Portal da Sa&#x000fa;de: rela&#x000e7;&#x000e3;o Nacional de Medicamentos Essenciais (RENAME)</article-title>. <year>2020</year>. [cited 2020 Dec]. <comment>Available in</comment>: <ext-link ext-link-type="uri" xlink:href="https://bvsms.saude.gov.br/bvs/publicacoes/relacao_medicamentos_rename_2020.pdf">https://bvsms.saude.gov.br/bvs/publicacoes/relacao_medicamentos_rename_2020.pdf</ext-link></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marmitt</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Bitencourt</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>GR</given-names></string-name></person-group>, et al. <article-title>Scientific production of plant species included in the Brazilian national list of medicinalplants of interest to the unified health system (RENISUS) from 2010 to 2013</article-title>. <source>J Chem Pharm Res</source>. <year>2016</year>; <volume>8</volume>: <fpage>123</fpage>&#x02013;1<lpage>32</lpage></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marmitt</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Bitencourt</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>ADCE</given-names></string-name>, et al</person-group>. <article-title>The healing properties of medicinal plants used in the Brazilian public health system: a systematic review</article-title>. <source>J Wound Care</source>. <year>2018a</year>;<volume>27</volume>(<issue>Sup6</issue>):<fpage>S4</fpage>&#x02013;<lpage>S13</lpage>.</mixed-citation><note><p><bold>&#x02022; References 14 nd 15 present the plants on the RENISUS list, used as keywords in the search for this systematic review.</bold></p></note></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marmitt</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Bitencourt</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>AC</given-names></string-name>, et al</person-group>. <article-title>Medicinal plants used in Brazil public health system with neuroprotective potential &#x02013; a systematic review</article-title>. Bol. Latinoam. Caribe Plantas Med. Arom&#x000e1;t. <year>2018b</year>;<volume>17</volume>:<fpage>84</fpage>&#x02013;<lpage>103</lpage>.</mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marmitt</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Bitencourt</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Da Silva</surname>
<given-names>GR</given-names></string-name>, et al</person-group>. <article-title>RENISUS plants and their potential antitumor effects in clinical trials and registered patents</article-title>. <source>Nutrit Cancer</source>. <year>2020</year>;<volume>72</volume>(<issue>7</issue>):<fpage>1</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">31842617</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Curcumin attenuates lupus nephritis upon interaction with regulatory T cells in New Zealand black/white mice</article-title>. <source>Br J Nut</source>. <year>2013</year>;<volume>110</volume>(<issue>1</issue>):<fpage>69</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee-Huang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>PL</given-names></string-name>, et al</person-group>. <article-title>Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1995</year>;<volume>92</volume>(<issue>19</issue>):<fpage>8818</fpage>&#x02013;<lpage>8822</lpage>.<pub-id pub-id-type="pmid">7568024</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanders</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Dean</surname>
<given-names>TS</given-names></string-name>, <string-name><surname>Grainger</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta (1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects</article-title>. <source>Am J Clin Nutr</source>. <year>2002</year>;<volume>76</volume>(<issue>2</issue>):<fpage>373</fpage>&#x02013;<lpage>377</lpage>.<pub-id pub-id-type="pmid">12145009</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name></person-group>. <article-title>Soybean isoflavones ameliorate ischemic cardiomyopathy by activating Nrf2-mediated antioxidant responses</article-title>. <source>Food &#x00026; Funct</source>. <year>2017</year>;<volume>8</volume>(<issue>8</issue>):<fpage>2935</fpage>&#x02013;<lpage>2944</lpage>.</mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Lau</surname>
<given-names>KK</given-names></string-name>, <string-name><surname>Yiu</surname>
<given-names>KH</given-names></string-name>, et al</person-group>. <article-title>Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke</article-title>. <source>Eur Heart J</source>. <year>2008</year>;<volume>29</volume>(<issue>22</issue>):<fpage>2800</fpage>&#x02013;<lpage>2807</lpage>.<pub-id pub-id-type="pmid">18812325</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yildiz</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Kumru</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Godekmerdan</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women</article-title>. <source>Int J Gynaecol Obstet</source>. <year>2005</year>;<volume>90</volume>(<issue>2</issue>):<fpage>128</fpage>&#x02013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">15970291</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saleh</surname>
<given-names>DO</given-names></string-name>, <string-name><surname>Abdel Jaleel</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>El-Awdan</surname>
<given-names>SA</given-names></string-name>, et al</person-group>. <article-title>Thioacetamide-induced liver injury: protective role of genistein</article-title>. <source>Can J Physiol Pharmacol</source>. <year>2014</year>;<volume>92</volume>(<issue>11</issue>):<fpage>965</fpage>&#x02013;<lpage>973</lpage>.<pub-id pub-id-type="pmid">25358106</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gupta</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Dongare</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mathur</surname>
<given-names>R</given-names></string-name>, et al</person-group>. <article-title>Genistein ameliorates cardiac inflammation and oxidative stress in streptozotocin-induced diabetic cardiomyopathy in rats</article-title>. <source>Mol Cell Biochem</source>. <year>2015</year>;<volume>408</volume>(<issue>1&#x02013;2</issue>):<fpage>63</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">26092427</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghaemi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Soleimanjahi</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Razeghi</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Genistein induces a protective immunomodulatory effect in a mouse model of cervical cancer</article-title>. <source>Iran J Immunol</source>. <year>2012</year>;<volume>9</volume>(<issue>2</issue>):<fpage>119</fpage>&#x02013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">22735799</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tyagi</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Srivastava</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sharan</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Daidzein prevents the increase in CD4+CD28 null T cells and B lymphopoesis in ovariectomized mice: a key mechanism for anti-osteoclastogenic effect</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>6</issue>):<fpage>e21216</fpage>.<pub-id pub-id-type="pmid">21731677</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>TL</given-names></string-name></person-group>. <article-title>Isoflavone daidzein regulates immune responses in the B6C3F1 and non-obese diabetic (NOD) mice</article-title>. Int Immunopharmacoly. <year>2019</year>;<volume>71</volume>:<fpage>277</fpage>&#x02013;<lpage>284</lpage>.</mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sakai</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Furoku</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Nakamoto</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>The soy isoflavone equol enhances antigen-specific IgE production in ovalbumin-immunized BALB/c mice</article-title>. <source>J. Nutr. Sci. Vitaminol</source>. <year>2010</year>;<volume>56</volume>(<issue>1</issue>):<fpage>72</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">20354350</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leray</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Freuchet</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Le Bloc&#x02019;h</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Effect of citrus polyphenol- and curcumin-supplemented diet on inflammatory state in obese cats</article-title>. <source>Br J Nutr</source>. <year>2011</year>;<volume>106</volume>(<issue>Suppl 1</issue>):<fpage>S198</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">22005428</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohammadi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Tamaddoni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Qujeq</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in &#x003b2;-thalassemia major patients: a double-blind randomized controlled clinical trial</article-title>. <source>Phytother Res</source>. <year>2018</year>;<volume>32</volume>(<issue>9</issue>):<fpage>1828</fpage>&#x02013;<lpage>1835</lpage>.<pub-id pub-id-type="pmid">29806132</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adibian</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hodaei</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Nikpayam</surname>
<given-names>O</given-names></string-name>, et al</person-group>. <article-title>The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Phytother Res</source>. <year>2019</year>;<volume>33</volume>(<issue>5</issue>):<fpage>1374</fpage>&#x02013;<lpage>1383</lpage>.<pub-id pub-id-type="pmid">30864188</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Almatroodi</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Alrumaihi</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Alsahli</surname>
<given-names>MA</given-names></string-name>, et al</person-group>. <article-title>(Curcumin, an active constituent of turmeric spice: implication in the prevention of lung injury induced by benzo(a) pyrene (bap) in rats</article-title>. <source>Molecules</source>. <year>2020</year>;<volume>25</volume>(<issue>3</issue>):<fpage>724</fpage>.</mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vanaie</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shahidi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Iraj</surname>
<given-names>B</given-names></string-name>, et al</person-group>. <article-title>Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy</article-title>. <source>J Res Med Sci</source>. <year>2019</year>;<volume>24</volume>(<issue>1</issue>):<fpage>77</fpage>.<pub-id pub-id-type="pmid">31523263</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>HG</given-names></string-name>, <string-name><surname>Choi</surname>
<given-names>JM</given-names></string-name></person-group>. <article-title>Curcumin Elevates T(FH) Cells and germinal center B cell response for antibody production in mice</article-title>. <source>Immune Net</source>. <year>2019</year>;<volume>19</volume>(<issue>5</issue>):<fpage>e35</fpage>.</mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tsao</surname>
<given-names>S-M</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>W-H</given-names></string-name>, <string-name><surname>Yin</surname>
<given-names>M-C</given-names></string-name></person-group>. <article-title>Two diallyl sulphides derived from garlic inhibit meticillin-resistant <italic>Staphylococcus aureus</italic> infection in diabetic mice</article-title>. <source>J Med Microbiol</source>. <year>2007</year>;<volume>56</volume>(<issue>6</issue>):<fpage>803</fpage>&#x02013;<lpage>808</lpage>.<pub-id pub-id-type="pmid">17510266</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>X</given-names></string-name>, et al</person-group>. <article-title>Pharmacological investigation of the anti-inflammation and anti-oxidation activities of diallyl disulfide in a rat emphysema model induced by cigarette smoke extract</article-title>. <source>Nutrients</source>. <year>2018</year>;<volume>10</volume>(<issue>1</issue>):<fpage>79</fpage>.</mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thomas</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Noordine</surname>
<given-names>M-L</given-names></string-name>, et al</person-group>. <article-title>Diallyl disulfide increases rat H-ferritin, L-ferritin and transferrin receptor genes in vitro in hepatic cells and in vivo in liver</article-title>. <source>J Nutrit</source>. <year>2002</year>;<volume>132</volume>(<issue>12</issue>):<fpage>3638</fpage>&#x02013;<lpage>3641</lpage>.<pub-id pub-id-type="pmid">12468600</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Souza</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Gasparotto</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Crestani</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Hypotensive mechanism of the extracts and artemetin isolated from Achillea millefolium L. (Asteraceae) in rats</article-title>. <source>Phytomedicine</source>. <year>2011</year>;<volume>18</volume>(<issue>10</issue>):<fpage>819</fpage>&#x02013;<lpage>825</lpage>.<pub-id pub-id-type="pmid">21420289</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thuy</surname>
<given-names>BTP</given-names></string-name>, <string-name><surname>My</surname>
<given-names>TTA</given-names></string-name>, <string-name><surname>Hai</surname>
<given-names>NTT</given-names></string-name>, et al</person-group>. <article-title>Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil</article-title>. <source>ACS Omega</source>. <year>2020</year>;<volume>5</volume>(<issue>14</issue>):<fpage>8312</fpage>&#x02013;<lpage>8320</lpage>.<pub-id pub-id-type="pmid">32363255</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takahashi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yoshiya</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Yoshizawa-Kumagaye</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean</article-title>. <source>Biomed Res</source>. <year>2015</year>;<volume>36</volume>(<issue>3</issue>):<fpage>219</fpage>&#x02013;<lpage>224</lpage>.<pub-id pub-id-type="pmid">26106051</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kesari</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Pratap</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dhankhar</surname>
<given-names>P</given-names></string-name>, et al</person-group>. <article-title>Structural characterization and in-silico analysis of momordica charantia 7S globulin for stability and ACE inhibition</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1160</fpage>.<pub-id pub-id-type="pmid">31980708</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname>
<given-names>S-Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>-C-C</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>Y-L</given-names></string-name>, et al</person-group>. <article-title>Antioxidant, anti-semicarbazide-sensitive amine oxidase, and anti-hypertensive activities of geraniin isolated from <italic>Phyllanthus urinaria</italic></article-title>. <source>Food and ChemToxicol</source>. <year>2008</year>;<volume>46</volume>(<issue>7</issue>):<fpage>2485</fpage>&#x02013;<lpage>2492</lpage>.</mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Mao</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Protective effects of allicin on streptozotocin-induced diabetic nephropathy in rats</article-title>. <source>J. Sci. Food Agric.</source>. <year>2017</year>;<volume>97</volume>(<issue>4</issue>):<fpage>1359</fpage>&#x02013;<lpage>1366</lpage>.<pub-id pub-id-type="pmid">27363537</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saravanan</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ponmurugan</surname>
<given-names>P</given-names></string-name></person-group>. <article-title>Antidiabetic effect of S-allylcysteine: effect on thyroid hormone and circulatory antioxidant system in experimental diabetic rats</article-title>. <source>J. Diabetes Complicat</source>. <year>2012</year>;<volume>26</volume>(<issue>4</issue>):<fpage>280</fpage>&#x02013;<lpage>285</lpage>.</mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arosio</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Gagliano</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Fusaro</surname>
<given-names>LM</given-names></string-name>, et al</person-group>. <article-title>Aloe-emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride</article-title>. <source>Toxicol Pharmacol</source>. <year>2000</year>;<volume>87</volume>(<issue>5</issue>):<fpage>229</fpage>&#x02013;<lpage>233</lpage>.</mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mostafa</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Abd El-Alim</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Asfour</surname>
<given-names>MH</given-names></string-name>, et al</person-group>. <article-title>Transdermal fennel essential oil nanoemulsions with promising hepatic dysfunction healing effect: <italic>in vitro</italic> and <italic>in vivo</italic> study</article-title>. <source>Pharm Dev Technol</source>. <year>2019</year>;<volume>24</volume>(<issue>6</issue>):<fpage>729</fpage>&#x02013;<lpage>738</lpage>.<pub-id pub-id-type="pmid">30775948</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Jiao</surname>
<given-names>Z</given-names></string-name>, et al</person-group>. <article-title>Phyllanthin and hypophyllanthin from <italic>Phyllanthus amarus</italic> ameliorates immune-inflammatory response in ovalbumin-induced asthma: role of IgE, Nrf2, iNOs, TNF-&#x003b1;, and IL&#x02019;s</article-title>. <source>Immunopharmacol Immunotoxicol</source>. <year>2019</year>;<volume>41</volume>(<issue>1</issue>):<fpage>55</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">30541359</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shanmugam</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Shanmugam</surname>
<given-names>KR</given-names></string-name>, <string-name><surname>Ravi</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Exploratory Studies of (-)-epicatechin, a bioactive compound of phyllanthus niruri, on the antioxidant enzymes and oxidative stress markers in d-galactosamine-induced hepatitis in rats: a Study with reference to clinical prospective</article-title>. <source>PharmacognMagaz</source>. <year>2017</year>;<volume>13</volume>(<issue>Suppl1</issue>):<fpage>S56</fpage>&#x02013;<lpage>S62</lpage>.</mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Foroutanfar</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mehri</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kamyar</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Protective effect of punicalagin, the main polyphenol compound of pomegranate, against acrylamide-induced neurotoxicity and hepatotoxicity in rats</article-title>. <source>Phytother Res</source>. <year>2020</year>;<volume>34</volume>(<issue>12</issue>):<page-range>3262&#x02013;3272</page-range>. in press.</mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>El-Sheakh</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Ghoneim</surname>
<given-names>HA</given-names></string-name>, <string-name><surname>Suddek</surname>
<given-names>GM</given-names></string-name>, et al</person-group>. <article-title>Attenuation of oxidative stress, inflammation, and endothelial dysfunction in hypercholesterolemic rabbits by allicin</article-title>. <source>Can J Physiol Pharmacol</source>. <year>2016</year>;<volume>94</volume>(<issue>2</issue>):<fpage>216</fpage>&#x02013;<lpage>224</lpage>.<pub-id pub-id-type="pmid">26618400</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Galal</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Mansour</surname>
<given-names>HH</given-names></string-name>, <string-name><surname>Elkhoely</surname>
<given-names>AA</given-names></string-name></person-group>. <article-title>Diallyl sulfide alleviates cyclophosphamide-induced nephropathic encephalopathy in rats</article-title>. <source>Toxicology Mechanisms and Methods</source>. <year>2020</year>;<volume>30</volume>(<issue>3</issue>):<fpage>208</fpage>&#x02013;<lpage>218</lpage>.<pub-id pub-id-type="pmid">31779506</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Panahi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ghanei</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bashiri</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial</article-title>. <source>Drug Res</source>. <year>2015</year>;<volume>65</volume>(<issue>11</issue>):<fpage>567</fpage>&#x02013;<lpage>573</lpage>.</mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lv</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Gu</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>1-Deoxynojirimycin in Mulberry (<italic>Morus indica</italic> L.) leaves ameliorates stable angina pectoris in patients with coronary heart disease by improving antioxidant and anti-inflammatory capacities</article-title>. <source>Front Pharmacol</source>. <year>2019</year>;<volume>10</volume>:<fpage>569</fpage>.<pub-id pub-id-type="pmid">31164826</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elseweidy</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Abdallah</surname>
<given-names>FR</given-names></string-name>, <string-name><surname>Younis</surname>
<given-names>NN</given-names></string-name>, et al</person-group>. <article-title>10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits</article-title>. <source>Atherosclerosis</source>. <year>2013</year>;<volume>231</volume>(<issue>2</issue>):<fpage>334</fpage>&#x02013;<lpage>340</lpage>.<pub-id pub-id-type="pmid">24267247</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saravanan</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ponmurugan</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Begum</surname>
<given-names>MS</given-names></string-name></person-group>. <article-title>Effect of S-allylcysteine, a sulphur containing amino acid on iron metabolism in streptozotocin induced diabetic rats</article-title>. <source>J Trace Elem Med Biol</source>. <year>2013</year>;<volume>27</volume>(<issue>2</issue>):<fpage>143</fpage>&#x02013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">22981633</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname>
<given-names>CL-T</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>S-L</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>Y-M</given-names></string-name>, et al</person-group>. <article-title>Cytopiloyne, a polyacetylenic glucoside, prevents type 1 diabetes in nonobese diabetic mice</article-title>. <source>J Immunol</source>. <year>2007a</year>;<volume>178</volume>(<issue>11</issue>):<fpage>6984</fpage>&#x02013;<lpage>6993</lpage>.<pub-id pub-id-type="pmid">17513748</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname>
<given-names>S-L</given-names></string-name>, <string-name><surname>Chiang</surname>
<given-names>Y-M</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>CL-T</given-names></string-name>, et al</person-group>. <article-title>Flavonoids, centaurein and centaureidin, from <italic>Bidens pilosa</italic>, stimulate IFN-gamma expression</article-title>. <source>J Ethnopharmacol</source>. <year>2007b</year>;<volume>112</volume>(<issue>2</issue>):<fpage>232</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">17408892</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname>
<given-names>S-L</given-names></string-name>, <string-name><surname>Yeh</surname>
<given-names>-H-H</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>Y-S</given-names></string-name>, et al</person-group>. <article-title>The effect of centaurein on interferon-gamma expression and Listeria infection in mice</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2007c</year>;<volume>219</volume>(<issue>1</issue>):<fpage>54</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">17229448</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>BL</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>YQ</given-names></string-name>, <string-name><surname>Ma</surname>
<given-names>BH</given-names></string-name>, et al</person-group>. <article-title>Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4R&#x003b1;-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice</article-title>. <source>Clin Exp Allergy</source>. <year>2018</year>;<volume>48</volume>(<issue>11</issue>):<fpage>1494</fpage>&#x02013;<lpage>1508</lpage>.<pub-id pub-id-type="pmid">30137697</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Devshilt</surname>
<given-names>I</given-names></string-name>, et al</person-group>. <article-title>Fennel main constituent, trans&#x02011;anethole treatment against LPS&#x02011;induced acute lung injury by regulation of Th17/Treg function</article-title>. <source>Mol Med Rep</source>. <year>2018</year>;<volume>18</volume>(<issue>2</issue>):<fpage>1369</fpage>&#x02013;<lpage>1376</lpage>.<pub-id pub-id-type="pmid">29901094</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tung</surname>
<given-names>CY</given-names></string-name>, <string-name><surname>Lewis</surname>
<given-names>DE</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant</article-title>. <source>Vaccine</source>. <year>2014</year>;<volume>32</volume>(<issue>42</issue>):<fpage>5411</fpage>&#x02013;<lpage>5419</lpage>.<pub-id pub-id-type="pmid">25131731</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Adachi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Shimizu</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Characterization of lectin isolated from <italic>momordica charantia</italic> seed as a B cell activator</article-title>. <source>Immunol Lett</source>. <year>2008</year>;<volume>121</volume>(<issue>2</issue>):<fpage>148</fpage>&#x02013;<lpage>156</lpage>.<pub-id pub-id-type="pmid">19014972</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shieh</surname>
<given-names>Y-H</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>H-M</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>-C-C</given-names></string-name>, et al</person-group>. <article-title>Zerumbone enhances the Th1 response and ameliorates ovalbumin-induced Th2 responses and airway inflammation in mice</article-title>. <source>Int Immunopharmacol</source>. <year>2015</year>;<volume>24</volume>(<issue>2</issue>):<fpage>383</fpage>&#x02013;<lpage>391</lpage>.<pub-id pub-id-type="pmid">25573403</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ju</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>YS</given-names></string-name>, et al</person-group>. <article-title>Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors</article-title>. <source>Int J Cancer</source>. <year>2012</year>;<volume>130</volume>(<issue>11</issue>):<fpage>2618</fpage>&#x02013;<lpage>2628</lpage>.<pub-id pub-id-type="pmid">21792901</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choi</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Jung</surname>
<given-names>UJ</given-names></string-name>, et al</person-group>. <article-title>Metabolic response of soy pinitol on lipid-lowering, antioxidant and hepatoprotective action in hamsters fed-high fat and high cholesterol diet</article-title>. <source>Mol Nut Food Res</source>. <year>2009</year>;<volume>53</volume>(<issue>6</issue>):<fpage>751</fpage>&#x02013;<lpage>759</lpage>.</mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gupta</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Kushwaha</surname>
<given-names>PP</given-names></string-name>, et al</person-group>. <article-title>Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies</article-title>. <source>J Biomol Struct Dyn</source>. <year>2020</year>;<volume>1-12</volume>. DOI:<pub-id pub-id-type="doi">10.1080/07391102.2020.1776157</pub-id>.</mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Newman</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Cragg</surname>
<given-names>GM</given-names></string-name></person-group>. <article-title>Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019</article-title>. <source>J Nat Prod</source>. <year>2020</year>;<volume>83</volume>(<issue>3</issue>):<fpage>770</fpage>&#x02013;<lpage>803</lpage>.<pub-id pub-id-type="pmid">32162523</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>He</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS)</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2012</year>;<volume>2012</volume>(<issue>10</issue>):<fpage>CD004882</fpage>.</mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shoji</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Furuishi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Yanase</surname>
<given-names>R</given-names></string-name>, et al</person-group>. <article-title>Allyl compounds selectively killed human immunodeficiency virus (type 1)-infected cells</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1993</year>;<volume>194</volume>(<issue>2</issue>):<fpage>610</fpage>&#x02013;<lpage>621</lpage>.<pub-id pub-id-type="pmid">8343148</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sawai</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Itoh</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ozaki</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin</article-title>. <source>Immunology</source>. <year>2008</year>;<volume>124</volume>(<issue>2</issue>):<fpage>155</fpage>&#x02013;<lpage>165</lpage>.<pub-id pub-id-type="pmid">18205793</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhen</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ye</surname>
<given-names>D-Y</given-names></string-name>, et al</person-group>. <article-title>Experimental study on the action of allitridin against human cytomegalovirus in vitro: inhibitory effects on immediate-early genes</article-title>. <source>Antiviral Res</source>. <year>2006</year>;<volume>72</volume>(<issue>1</issue>):<fpage>68</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">16844239</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rouf</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Uddin</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Sarker</surname>
<given-names>DK</given-names></string-name>, et al</person-group>. <article-title>Antiviral potential of garlic (<italic>Allium sativum</italic>) and its organosulfur compounds: a systematic update of pre-clinical and clinical data</article-title>. <source>Trends Food Sci Technol</source>. <year>2020</year>;<volume>104</volume>:<fpage>219</fpage>&#x02013;<lpage>234</lpage>.<pub-id pub-id-type="pmid">32836826</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bourne</surname>
<given-names>KZ</given-names></string-name>, <string-name><surname>Bourne</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Reising</surname>
<given-names>SF</given-names></string-name>, et al</person-group>. <article-title>Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2</article-title>. <source>Antivir Res</source>. <year>1999</year>;<volume>42</volume>(<issue>3</issue>):<fpage>219</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">10443534</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jennings</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Parks</surname>
<given-names>RJ</given-names></string-name></person-group>. <article-title>Curcumin as an antiviral agent</article-title>. <source>Viruses</source>. <year>2020</year>;<volume>12</volume>(<issue>11</issue>):<fpage>1242</fpage>.</mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huscenot</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Galland</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ouvrat</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>SARS-CoV-2-associated cold agglutinin disease: a report of two cases</article-title>. <source>Ann Hematol</source>. <year>2020</year>;<volume>11</volume>:<fpage>1</fpage>&#x02013;<lpage>2</lpage>.</mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wessling-Resnick</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Crossing the iron gate: why and how transferrin receptors mediate viral entry</article-title>. <source>Annu. Rev. Nutr</source>. <year>2018</year>;<volume>38</volume>(<issue>1</issue>):<fpage>431</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">29852086</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>C</given-names></string-name>, et al</person-group>. <article-title>Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</article-title>. <source>Sci China Life Sci</source>. <year>2020</year>;<volume>63</volume>(<issue>3</issue>):<fpage>364</fpage>&#x02013;<lpage>374</lpage>.<pub-id pub-id-type="pmid">32048163</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uhlig</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Silva</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Deckert</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis</article-title>. <source>Crit Care</source>. <year>2014</year>;<volume>18</volume>(<issue>1</issue>):<fpage>R10</fpage>.<pub-id pub-id-type="pmid">24405693</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Orhan</surname>
<given-names>IE</given-names></string-name>, <string-name><surname>Deniz</surname>
<given-names>FSS</given-names></string-name></person-group>. <article-title>Natural products as potential leads against coronaviruses: could they be encouraging structural models against SARS CoV&#x02011;2? Nat</article-title>. <source>Prod. Bioprospect</source>. <year>2020</year>;<volume>10</volume>(<issue>4</issue>):<fpage>171</fpage>&#x02013;<lpage>186</lpage>.</mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>KI</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Plasma CRP level is positively associated with the severity of COVID-19</article-title>. <source>Ann Clin Microbiol Antimicrob</source>. <year>2020</year>;<volume>19</volume>(<issue>1</issue>):<fpage>18</fpage>.<pub-id pub-id-type="pmid">32414383</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Low serum level of apolipoprotein A1 is an indicator of severity in patients with coronavirus disease 2019</article-title>. <source>Europe PMC</source>. <year>2020</year>; in press. DOI:<pub-id pub-id-type="doi">10.21203/rs.3.rs-33301/v1</pub-id>.</mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bansal</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Cardiovascular disease and COVID-19</article-title>. <source>Diabetol Metab Syndr</source>. <year>2020</year>;<volume>14</volume>(<issue>3</issue>):<fpage>247</fpage>&#x02013;<lpage>250</lpage>.</mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ramasamy</surname>
<given-names>MN</given-names></string-name>, <string-name><surname>Minassian</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Ewer</surname>
<given-names>KJ</given-names></string-name>, et al</person-group>. <article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>396</volume>(<issue>10267</issue>):<page-range>1979&#x02013;1993</page-range>. In press.</mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zeng</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Pan</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#x02013;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet</source>. <year>2020</year>. in press. DOI:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id>.</mixed-citation><note><p><bold>&#x02022; References 84 and 85 show two vaccines already approved for use, that induced the immune response by T cell activity. In this review, 16 studies show that compounds induce the stimulate T cell responses.</bold></p></note></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Din</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Waris</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Retracted: phytotherapeutic options for the treatment of COVID-19: a concise viewpoint</article-title>. <source>Phytotherapy Research</source>. <year>2020</year>;<volume>34</volume>(<issue>10</issue>):<page-range>2431&#x02013;2437</page-range>. in press.</mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grifoni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Weiskopf</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ramirez</surname>
<given-names>SI</given-names></string-name>, et al</person-group>. <article-title>Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals</article-title>. <source>Cell</source>. <year>2020</year>;<volume>181</volume>(<issue>7</issue>):<fpage>1489</fpage>&#x02013;<lpage>1501</lpage>.<pub-id pub-id-type="pmid">32473127</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sekine</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Perez-Potti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rivera-Ballesteros</surname>
<given-names>O</given-names></string-name>, et al</person-group>. <article-title>Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19</article-title>. <source>Cell</source>. <year>2020</year>;<volume>183</volume>(<issue>1</issue>):<fpage>158</fpage>&#x02013;<lpage>168.e14</lpage>.<pub-id pub-id-type="pmid">32979941</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cui</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>ZL</given-names></string-name></person-group>. <article-title>Origin and evolution of pathogenic coronaviruses</article-title>. <source>Nat Rev Microbiol</source>. <year>2019</year>;<volume>17</volume>(<issue>3</issue>):<fpage>181</fpage>&#x02013;<lpage>192</lpage>.<pub-id pub-id-type="pmid">30531947</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Le Bert</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>AT</given-names></string-name>, <string-name><surname>Kunasegaran</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title>. <source>Nature</source>. <year>2020</year>;<volume>584</volume>(<issue>7821</issue>):<fpage>457</fpage>&#x02013;<lpage>462</lpage>.<pub-id pub-id-type="pmid">32668444</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mateus</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Grifoni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tarke</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title>. <source>Science</source>. <year>2020</year>;<volume>370</volume>(<issue>6512</issue>):<fpage>89</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">32753554</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Long</surname>
<given-names>QX</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>BZ</given-names></string-name>, <string-name><surname>Deng</surname>
<given-names>HJ</given-names></string-name>, et al</person-group>. <article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>6</issue>):<fpage>845</fpage>&#x02013;<lpage>848</lpage>.<pub-id pub-id-type="pmid">32350462</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sabino</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Buss</surname>
<given-names>LF</given-names></string-name>, <string-name><surname>Carvalho</surname>
<given-names>MPS</given-names></string-name>, et al</person-group>. <article-title>Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>(<issue>10273</issue>):P.<page-range>452&#x02013;455</page-range>.</mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ruan</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Mechanism of dayuanyin in the treatment of coronavirus disease 2019 based on network pharmacology and molecular docking</article-title>. <source>Chinese Med</source>. <year>2020</year>;<volume>15</volume>(<issue>1</issue>):<fpage>62</fpage>.</mixed-citation></ref></ref-list></back></article>